Agilent Technologies Stock News

The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

SAN FRANCISCO , March 10, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Biopharmaceutical Bioseparation Systems - Global Market Trajectory & Analytics" . The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What''s New for 2022? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to our digital archives and MarketGlass Research Platform Complimentary updates for one year Edition: 17; Released: February 2022 Executive Pool: 4113 Companies: 52 - Players covered include 3M Purification Inc.; Agilent Technologies, Inc.; Alfa Wassermann Separation Technologies LLC; Flottweg Separation Technology; GE Healthcare Life Sciences; GEA Westfalia Separator Group GmbH; KNAUER Wissenschaftliche Geräte GmbH; Konik Nanobiotech SL; Merck KGaA; Pall Corporation; ProMetic Life Sciences Inc.; Repligen Corp.; Sartorius Stedim Biotech; Thermo Fischer Scientific Inc.; Tosoh Bioscience Inc.; YMC Europe GMBH and Others.

WASHINGTON, March 07, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Genomics in Cancer Care Market finds that rising demand for technologically advanced & cost-efficient diagnostic technology and increasing demand for diagnostics centres are augmenting the growth of Genomics in Cancer Care Market in upcoming years. In addition, growing research activities for the development of novel treatment therapies and increasing funding for the development of pharmaceutical and biotech industry are some other important parameters that bolstering the market demand in the projected time span. The total Global Genomics in Cancer Care Market is estimated to reach USD 40.5 Billion by 2028. The market stood at a revenue of USD 12.1 Billion in the year 2021, and expected to grow at a Compound Annual Growth Rate (CAGR) of 16.1%, states Vantage Market Research, in a report, titled " Genomics in Cancer Care Market by Product (Instruments, Consumables, Services), by Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research), by Technology (Genome Sequencing, PCR, Microarrays, Nucleic Acid Extraction & Purification), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Dublin, March 04, 2022 (GLOBE NEWSWIRE) -- The "Flow Cytometry Global Market Report 2022, By Type, By Technology, By End User, By Application" report has been added to ResearchAndMarkets.com''s offering. This report provides strategists, marketers and senior management with the critical information they need to assess the global flow cytometry market. The report gives a guide to the flow cytometry market which will be shaping and changing our lives over the next ten years and beyond, including the market''s response to the challenge of the global pandemic Reasons to Purchase Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies. Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates. Create regional and country strategies on the basis of local data and analysis. Identify growth segments for investment. Outperform competitors using forecast data and the drivers and trends shaping the market.

Agilent Technologies (NYSE: A ) has outperformed the market over the past 10 years by 3.57% on an annualized basis. Buying $1,000 In A: 10 years ago, an investor could have purchased 32.69 shares of Agilent Technologies at the time with $1,000. This investment in A would have produced an average … Full story available on Benzinga.com

La Jolla, California-based life sciences company, Singular Genomics Systems (OMIC), announced two separate partnerships with Agilent Technologies (A) and COVID-19 test maker QIAGEN…

Agilent and UVM announce the Agilent Laboratory for Chemical Analysis (ALCA) Vermont Biz

Agilent Technologies Inc''s (NYSE: A ) short percent of float has risen 7.36% since its last report. The company recently reported that it has 5.24 million shares sold short , which is 1.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.1 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of … Full story available on Benzinga.com

Agilent (A) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earn

Agilent (A) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earn

Element Biosciences Inc., developer of a new and disruptive DNA sequencing platform, announced a partnership with Agilent Technologies demonstrating integration of Element’s AVITI System with Agilent Technologies’ industry-leading SureSelect target enrichment panels, providing customers greater access to these genomic tools. Latest Aithority Insights: Yanmar Invests $21 Million in GetMyBoat as Part of Series B Funding to […] The post Element Biosciences Partners with Agilent Technologies To Validate SureSelect Target Enrichment Panels on Element’s AVITI System appeared first on AiThority .

Over the past 3 months, 4 analysts have published their opinion on Agilent Technologies (NYSE:A) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a

Over the past 3 months, 4 analysts have published their opinion on Agilent Technologies (NYSE: A ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 1 0 0 Last 30D 1 2 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Agilent Technologies has an average price target of $156.25 with a high … Full story available on Benzinga.com